Items in cart [4] Questions? Call 888-624-8373

PAPERBACK list:$39.00 Web:$35.10 add to cart PDF BOOK your price: $30.00 add to cart Rights & Permissions Free Resources PDF EXECUTIVE SUMMARY Display this book on your site! Related Titles Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem The Future of Drug Safety: Promoting and Protecting the Health of the Public Other Related Titles Halcion: An Independent Assessment of Safety and Efficacy Data (1997) Institute of Medicine (IOM) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 107   E-mail  Facebook  Digg  Stumble  Twitter More The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. A FDA Safety Tables A-1   Non-Geriatric Studies: Anxiety,   108 A-2   Non-Geriatric Studies: Confusion,   109 A-3   Non-Geriatric Studies: Depression,   110 A-4   Non-Geriatric Studies: Irritability,   111 A-5   Non-Geriatric Studies: Memory Impairment,   112 A-6   Non-Geriatric Studies: All Psychiatric,   113 A-7   Non-Geriatric Studies: Sedative/Hypnotic,   114 A-8   Geriatric Studies: Anxiety,   115 A-9   Geriatric Studies: Confusion,   116 A-10   Geriatric Studies: Depression,   117 A-11   Geriatric Studies: Irritability,   118 A-12   Geriatric Studies: Memory Impairment,   119 A-13   Geriatric Studies: All Psychiatric,   120 A-14   Non-Geriatric Studies,   121 A-15   Geriatric Studies,   122 Source of all tables:. Laughren, T.P. and H. Lee. 1992. Review of adverse event data in Upjohn-sponsored clinical studies of Halcion (triazolam), NDA 17-892. Report made to U.S. Food and Drug Administration. Page 107 Front Matter (R1-R18) Executive Summary (1-9) Introduction (10-19) Assessment of Efficacy Data (20-48) Assessment of Safety Data (49-93) Additional Comments on Broader Implications (94-96) References (97-106) Appendix A: FDA Safety Tables (107-122) Appendix B: Summary Tables of Literature Reviewed for Safety of Halcion (123-142) Appendix C: Glossary (143-144) Appendix D: Acronyms (145-145) Appendix E: Resources Reviewed by the Committee (146-149) Appendix F: Upjohn Consent to Disclosure (150-152) Appendix G: Committee and Staff Biographies (153-158)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 107
Halcion: An Independent Assessment of Safety and Efficacy Data A FDA Safety Tables A-1   Non-Geriatric Studies: Anxiety,   108 A-2   Non-Geriatric Studies: Confusion,   109 A-3   Non-Geriatric Studies: Depression,   110 A-4   Non-Geriatric Studies: Irritability,   111 A-5   Non-Geriatric Studies: Memory Impairment,   112 A-6   Non-Geriatric Studies: All Psychiatric,   113 A-7   Non-Geriatric Studies: Sedative/Hypnotic,   114 A-8   Geriatric Studies: Anxiety,   115 A-9   Geriatric Studies: Confusion,   116 A-10   Geriatric Studies: Depression,   117 A-11   Geriatric Studies: Irritability,   118 A-12   Geriatric Studies: Memory Impairment,   119 A-13   Geriatric Studies: All Psychiatric,   120 A-14   Non-Geriatric Studies,   121 A-15   Geriatric Studies,   122 Source of all tables:. Laughren, T.P. and H. Lee. 1992. Review of adverse event data in Upjohn-sponsored clinical studies of Halcion (triazolam), NDA 17-892. Report made to U.S. Food and Drug Administration.

OCR for page 108
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-1 Non-Geriatric Studies: Anxiety TABLE 5.4 NON-GERIATRIC STUDIES: ANXIETY     DOSE (MG)   % WITH ANXIETY STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6401 1 .25 — 70 2.9 — 2.9 2401 1 .25-.5 — 145 4.4 — 1.3 6400 1 .25-.5 15-30 105 7.5 3.8 — 6041 1 .5 — 143 4.3 — 2.7 6042 1 .5 30 127 4.7 0.0 — 6004 1 .6 30 37 6.3 23.8 — 6043 2 .5 — 277 8.0 — 5.0 6016 2 .5 30 30 7.1 0.0 — 6044 2 .5 30 232 6.9 5.2 — 6402 4 .25 30 81 20.4 22.2 — 6045 4 .5 — 62 16.1 — 12.9 6046 4 .5 30 103 10.9 2.0 — 6047 6 .5 — 125 15.0 — 3.1 6048 6 .5 30 145 4.1 5.6 — 6023B 12 .5 30 18 8.3 0.0 — 6023 12 .6 30 51 9.1 0.0 — 6049 13 .5 30 139 13.5 8.2 —

OCR for page 109
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-2 Non-Geriatric Studies: Confusion TABLE 5.5 NON-GERIATRIC STUDIES: CONFUSION     DOSE (MG)   % WITH CONFUSION STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6401 1 .25 — 70 0.0 - 0.0 2401 1 .25-.5 — 145 0.0 — 0.0 6400 1 .25-.5 15-30 105 0.0 0.0 — 6041 1 .5 — 143 0.0 — 0.0 6042 1 .5 30 127 1.6 0.0 — 6004 1 .6 30 37 12.5 0.0 — 6043 2 .5 — 277 0.0 — 0.7 6016 2 .5 30 30 0.0 0.0 — 6044 2 .5 30 232 0.0 0.0 — 6402 4 .25 30 81 0.0 0.0 — 6045 4 .5 — 6'2 6.5 — 0.0 6046 4 .5 30 10.3 0.0 0.0 — 6047 6 .5 — 125 0.0 — 0.0 6048 6 .5 30 145 0.0 0.0 — 6023B 12 .5 30 18 0.0 0.0 — 6023 12 .6 30 51 3.0 5.6 — 6049 13 .5 30 139 2.7 0.0 —

OCR for page 110
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-3 Non-Geriatric Studies: Depression TABLE 5.6 NON-GERIATRIC STUDIES: DEPRESSION     DOSE (MG)   % WITH DEPRESSION STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6401 1 .25 — 70 0.0 — 0.0 2401 1 .25-.5 — 145 0.0 — 0.0 66400 1 .25-.5 15-30 105 0.0 0.0 — 6041 1 .5 — 143 1.4 — 2.7 6042 1 .5 3.0 127 0.0 0.0 — 6004 1 .6 30 37 0.0 0.0 — 6043 2 .5 — 277 2.2 — 0.7 6016 2 .5 30 30 0.0 0.0 — 6044 2 .5 30 232 2.6 3.4 — 6402 4 .25 30 81 3.7 0.0 — 6045 4 .5 — 62 0.0 — 0.0 6046 4 .5 30 103 1.8 0.0 — 6047 6 .5 — 125 0.0 — 0.0 6048 6 .5 30 145 4.1 4.2 — 60238 12 .5 30 18 0.0 0.0 — 6023 12 6 30 51 3.0 0.0 — 6049 13 .5 30 139 6.8 6.8 —

OCR for page 111
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-4 Non-Geriatric Studies: Irritability TABLE 5.7 NON-GERIATRIC STUDIES: IRRITABILITY     DOSE (MG)   % WITH IRRITABILITY STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6401 1 .25 — 70 0.0 — 0.0 2401 1 .25-.5 — 145 1.5 — 3.9 6400 1 .25-.5 15-30 105 0.0 0.0 — 6041 1 .5 — 143 0.0 — 0.0 6042 1 .5 30 127 3.1 1.6 — 6004 1 .6 30 37 0.0 0.0 — 6043 2 .5 — 277 0.0 — 2.2 6016 2 .5 30 30 0.0 0.0 — 6044 2 .5 30 232 0.0 1.7 — 6402 4 .25 30 81 0.0 3.7 — 6045 4 .5 — 62 0.0 — 0.0 6046 4 .5 30 103 1.8 0.0 — 6047 6 .5 — 125 0.0 — 0.0 6048 6 .5 30 145 0.0 0.0 — 6023B 12 .5 30 18 0.0 0.0 — 6023 12 .6 30 51 0.0 0.0 — 6049 13 .5 30 139 1.4 0.0 —

OCR for page 112
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-5 Non-Geriatric Studies: Memory Impairment TABLE 5.8 NON-GERIATRIC STUDIES: MEMORY IMPAIRMENT     DOSE (MG)   % WITH MEMORY IMPAIRMENT STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6401 1 .25 — 70 0.0 — 0.0 2401 1 .25-.5 — 145 0.0 — 0.0 6400 1 .25-.5 15-30 105 0.0 0.0 — 6041 1 .5 — 143 0.0 — 0.0 6042 1 .5 30 127 1.6 1.6 — 6004 1 .6 30 37 6.3 0.0 — 6043 2 .5 — 277 0.0 — 0.0 6016 2 .5 30 30 0.0 0.0 — 6044 2 .5 30 232 0.0 0.0 — 6402 4 .25 30 81 0.0 0.0 — 6045 4 .5 — 62 0.0 — 0.0 6046 4 .5 30 103 0.0 0.0 — 6047 6 .5 — 125 1.7 — 0.0 6048 6 .5 30 145 1.4 0.0 — 6023B 12 .5 30 18 8.3 0.0 — 6023 12 .6 30 51 15.2 0.0 — 6049 13 .5 30 139 6.8 0.0 —

OCR for page 113
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-6 Non-Geriatric Studies: All Psychiatric TABLE 5.9 NON-GERIATRIC STUDIES: 'ALL PSYCHIATRIC'     DOSE (MG)   % WITH 'ALL PSYCHIATRIC' STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6401 1 .25 — 70 5.7 — 2.9 2041 1 .25-.5 — 145 5.9 — 3.9 6400 1 .25-.5 15-30 105 11.3 3.8 — 6041 1 .5 — 143 5.7 — 5.5 6042 1 .5 30 127 7.8 3.2 — 6004 1 .6 30 37 25.0 42.9 — 6043 2 .5 — 277 10.9 — 10.1 6016 2 .5 30 30 7.1 0.0 — 6044 2 .5 30 232 9.5 9.5 — 6402 4 .25 30 81 25.9 29.6 — 6045 4 .5 — 62 29.0 — 12.9 6046 4 .5 30 103 12.7 0.0 — 6047 6 .5 — 125 15.0 — 7.7 6048 6 .5 30 145 9.5 0.0 — 6023B 1.2 .5 30 18 8.3 16.7 — 6023 12 .6 30 51 21.2 22.2 — 6049 13 .5 30 139 23.0 15.1 —

OCR for page 114
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-7 Non-Geriatric Studies: Sedative/Hypnotic TABLE 5.10 NON-GERIATRIC STUDIES: 'SEDATIVE/HYPNOTIC'     DOSE (MG)   % WITH 'SEDATIVE HYPNOTIC' STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6401 1 .25 — 70 17.1 — 11.4 2401 1 .25-.5 — 145 75.0 — 84.4 6400 1 .25-.5 15-30 105 20.8 21.2 — 6041 1 .5 — 143 24.3 — 12.3 6042 1 ..5 30 127 21.9 17.5 — 6004 1 .6 30 37 50.0 47.6 — 6043 2 .5 — 277 35.5 — 19.4 6016 2 .5 30 30 14.3 25.0 — 6044 2 .5 30 232 37.1 44.0 — 6402 4 .25 30 81 33.3 59.3 — 6045 4 .5 — 62 54.8 — 12.9 6046 4 .5 30 103 43.6 36.0 — 6047 6 .5 — 125 36.7 — 13.8 6048 6 .5 30 145 25.7 31.0 — 6023B 12 .5 30 18 41.7 50.0 — 6023 12 .6 30 51 33.3 77.8 — 6049 13 .5 30 139 37.8 42.5 —

OCR for page 115
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-8 Geriatric Studies: Anxiety TABLE 5.11 GERIATRIC STUDIES: ANXIETY     DOSE (MG)   % WITH ANXIETY STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6417 1 .125 — 90 2.2 — 9.1 6417A 1 .125-.25 — 37 0.0 — 15.8 6061 1 .25 — 59 0.0 — 0.0 6062 1 .25 15 71 0.0 0.0 — 6063 2 .25 — 38 5.6 — 10.0 6064 2 .25 15 43 10.0 0.0 — 6065 4 .25 15 41 14.3 0.0 0.0 2601 4 .25-.5 15-30 121 30.0 17.5 14.6

OCR for page 116
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-9 Geriatric Studies: Confusion TABLE 5.12 GERIATRIC STUDIES: CONFUSION     DOSE (MG)   % WITH CONFUSION STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6417 1 .125 — 90 0.0 — 2.3 6417A 1 .125-.25 — 37 0.0 — 0.0 6061 1 .25 — 59 0.0 — 0.0 6062 1 .25 15 71 0.0 0.0 — 6063 2 .25 — 38 5.6 — 0.0 6064 2 .25 15 43 0.0 4.3 — 6065 4 .25 15 41 0.0 0.0 0.0 2601 4 .25-.5 15-30 121 5.0 2.5 2.4

OCR for page 117
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-10 Geriatric Studies: Depression TABLE 5.13 GERIATRIC STUDIES: DEPRESSION     DOSE (MG)   % WITH DEPRESSION STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6417 1 .125 — 90 0.0 — 0.0 6417A 1 .125-.25 — 37 0.0 — 0.0 6061 1 .25 — 59 0.0 — 0.0 6062 1 .25 15 71 0.0 0.0 — 6063 2 .25 — 38 5.6 — 0.0 6064 2 .25 15 43 10.0 0.0 — 6065 4 .25 15 41 0.0 0.0 0.0 2601 4 .25-.5 15-30 121 7.5 5.0 7.3

OCR for page 118
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-11 Geriatric Studies: Irritability TABLE 5.14 GERIATRIC STUDIES: IRRITABILITY     DOSE (MG)   % WITH IRRITABILITY STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6417 1 .125 — 90 0.0 — 0.0 6417A 1 .125-.25 — 37 0.0 — 0.0 6061 1 .25 — 59 0.0 — 0.0 6062 1 .25 15 71 0.0 0.0 — 6063 2 .25 — 38 0.0 — 0.0 6064 2 .25 15 43 0.0 0.0 — 6065 4 .25 1.5 41 7.1 0.0 0.0 2601 4 .25-.5 15-30 121 5.0 0.0 2.4

OCR for page 119
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-12 Geriatric Studies: Memory Impairment TABLE 5.15 GERIATRIC STUDIES: MEMORY IMPAIRMENT     DOSE (MG)   % WITH MEMORY IMPAIRMENT STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6417 1 .125 — 90 0.0 — 0.0 6417A 1 .125-.25 — 37 0.0 — 0.0 6061 1 .25 — 59 0.0 — 0.0 6062 1 .25 15 71 0.0 0.0 — 6063 2 .25 — 38 0.0 — 0.0 6064 2 .25 15 43 0.0 0.0 — 6065 4 .25 15 41 0.0 0.0 0.0 2601 4 .25-.5 15-30 121 2.5 0.0 0.0

OCR for page 120
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-13 Geriatric Studies: All Psychiatric TABLE 5.16 GERIATRIC STUDIES: 'ALL PSYCHIATRIC'     DOSE (MG)   % WITH 'ALL PSYCHIATRIC' STUDY WEEKS TRZ FLZ N TRZ FLZ PBO 6417 1 .125 — 90 2.2 — 13.6 6417A 1 .1250.25 — 37 0.0 — 15.8 6061 1 .25 — 59 0.0 — 0.0 6062 1 .25 15 71 0.0 0.0 — 6063 2 .25 — 38 11.1 — 10.1 6064 2 25 15 43 15.0 4.3 — 6065 4 .25 15 41 14.3 0.0 0.0 2601 4 .25-.5 15-30 121 47.5 32.5 26.8

OCR for page 121
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-14 Non-Geriatric Studies TABLE 2.2: NON-GERIATRIC STUDIES     DOSE (MG) GROUPS/SAMPLE SIZE STUDY WEEKS TRZ FLZ TRZ FLZ PBO 6401 1 .25 — 35 — 35 2401 1 .25-.5 — 66 — 77 6400 1 .25-.5 15-30 53 52 — 6041 1 .5 — 70 — 72 6042 1 .5 30 62 59 — 6004 1 .6 30 16 21 — 6043 2 .5 — 138 — 135 6016 2 .5 30 14 16 — 6044 2 .5 30 112 110 — 6402 4 .25 30 54 27 — 6045 4 .5 — 31 — 31 6046 4 .5 30 55 50 — 6047 6 .5 — 59 — 64 6048 6 .5 30 72 71 — 6023B 12 .5 30 9 6 — 6023 12 .6 30 33 18 — 6049 13 .5 30 74 73 —

OCR for page 122
Halcion: An Independent Assessment of Safety and Efficacy Data TABLE A-15 Geriatric Studies TABLE 2.3: GERIATRIC STUDIES     DOSE (MG) GROUPS/SAMPLE SIZE STUDY WEEKS TRZ FLZ TRZ FLZ PBO 6417 1 .125 — 46 — 44 6417A 1 .125-.25 — 18 — 19 6061 1 .25 — 31 — 28 6062 1 .25 15 36 35 — 6063 2 .25 — 18 — 20 6064 2 .25 15 20 23 — 6065 4 .25 15 14 13 14 2601 4 .25-.5 15-30 32 33 27

Representative terms from entire chapter:

anxiety geriatric